Transplantation Adjuvant in Cell Therapy Using Neural Progenitor Cells
AssigneeSumitomo Dainippon Pharma Co., Ltd.
InventorJun Takahashi
Life of this patent
Estimating the term…
Abstract
The present invention provides a transplantation adjuvant for neural progenitor cells containing valproic acid and/or zonisamide as an active ingredient.
Claims21
(canceled)
The method according to claim 4, wherein the administering is performed no sooner than two days before the transplanting.
The method according to claim 4, wherein the neural progenitor cells are derived from iPS cells.
A method of treating a degenerative disease of dopaminergic neurons in a subject in need thereof, comprising
- transplanting neural progenitor cells in the subject, and
- administering an effective amount of valprotic acid and/or zonisamide to the subject before, after, or simultaneously with the transplanting.
A method of improving retention rate of dopaminergic nerve cells induced from neural progenitor cells after transplantation, comprising
- transplanting neural progenitor cells in a subject, and
- administering an effective amount of valproic acid and/or zonisamide to the subject before, after, or simultaneously with the transplanting.
Dependencies are inferred from the claim text.